Apixaban Dosing for VTE Prophylaxis After Knee Replacement
For VTE prophylaxis after knee replacement surgery, use apixaban 2.5 mg orally twice daily, starting 12 to 24 hours after surgery, and continue for 10 to 14 days.
Dosing Regimen
The evidence-based dosing for post-operative knee arthroplasty is straightforward 1, 2:
- Dose: 2.5 mg orally twice daily
- Initiation: 12 to 24 hours after wound closure
- Duration: 10 to 14 days (for total knee replacement)
This regimen was validated in the ADVANCE-1 and ADVANCE-2 trials involving over 6,000 knee replacement patients 1. The FDA-approved label confirms this exact dosing schedule 2.
Evidence Supporting This Dose
The ADVANCE-2 trial demonstrated superiority of apixaban 2.5 mg twice daily over enoxaparin 40 mg once daily (the European standard), with VTE rates of 15.1% versus 24.4% (RR 0.62, P<0.0001) 1. Importantly, major or clinically relevant bleeding was numerically lower with apixaban (3.5% vs 4.8%) 1.
The ADVANCE-1 trial, comparing apixaban to the US enoxaparin regimen (30 mg twice daily), showed similar efficacy but significantly less bleeding with apixaban (2.9% vs 4.3%, P=0.03) 1, 3.
Critical Timing Considerations
Do not start apixaban earlier than 12 hours post-surgery. The trials specifically initiated dosing 12-24 hours after wound closure to balance thromboprophylaxis with surgical hemostasis 1. Starting too early increases bleeding risk without proven benefit.
Important Caveats
Renal Function
No dose adjustment is needed for standard prophylaxis in knee replacement unless creatinine clearance is <30 mL/min 4. However, monitor renal function postoperatively as surgical stress can affect kidney function 4.
Drug Interactions
Avoid concurrent use with strong dual inhibitors of CYP3A4 and P-glycoprotein (ketoconazole, ritonavir) as these significantly increase apixaban levels 1.
Neuraxial Anesthesia
If spinal or epidural anesthesia was used, ensure adequate time has elapsed before starting apixaban. The French perioperative guidelines emphasize not administering therapeutic anticoagulation with an epidural catheter in place 4.
Transitioning Anticoagulation
If the patient requires continued anticoagulation beyond the prophylactic period (e.g., for atrial fibrillation or prior VTE), do not overlap prophylactic-dose apixaban with therapeutic anticoagulation 4. When transitioning to therapeutic dosing:
- Wait 12 hours after the last prophylactic dose of LMWH before starting therapeutic apixaban 4
- Therapeutic VTE treatment dosing is 10 mg twice daily for 7 days, then 5 mg twice daily 5, 6, 2
Common Pitfall to Avoid
Do not use the 5 mg twice daily dose for post-operative prophylaxis. This is the therapeutic dose for atrial fibrillation or VTE treatment, not the prophylactic dose 2. The 2.5 mg twice daily regimen is specifically validated and approved for orthopedic surgery prophylaxis 1, 2.